Form 4: Apogee Therapeutics CEO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Apogee Therapeutics CEO Michael Henderson sold 19,990 shares of common stock on November 13, 2025, through a pre-arranged Rule 10b5-1 trading plan.
Summary
- Michael Thomas Henderson, Chief Executive Officer and Director of Apogee Therapeutics, Inc. (APGE), reported sales of common stock.
- Transactions occurred on November 13, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.
- A total of 19,990 shares of common stock were disposed of in four separate transactions.
- The shares were sold at weighted average prices ranging from $61.93 to $64.52.
- Specific transaction details include: 3,340 shares at $61.93, 14,774 shares at $63.14, 1,786 shares at $63.89, and 100 shares at $64.52.
- Following these transactions, Michael Henderson directly beneficially owns 1,272,987 shares of Apogee Therapeutics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the reported transactions are routine insider sales executed under a pre-arranged 10b5-1 trading plan, which typically indicates a planned diversification or liquidity event rather than a reaction to new company-specific information.
Negatives
- The Chief Executive Officer and Director sold a notable number of shares, which could be interpreted by some investors as a lack of confidence, although mitigated by the 10b5-1 plan.
Industry Context
Insider sales under Rule 10b5-1 plans are a common practice across industries, allowing executives to diversify holdings and manage liquidity in a pre-scheduled, compliant manner, reducing the perception of trading on non-public information.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | The reported stock sales were executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025, demonstrating a structured approach to insider transactions. | 08/13/2025 | The use of a 10b5-1 plan enhances transparency and mitigates concerns about insiders trading on material non-public information, aligning with best practices in corporate governance. |
Stakeholder Impact
- Shareholders: The sale represents a routine diversification or liquidity event for the CEO, pre-scheduled under a 10b5-1 plan, and is unlikely to have a significant direct impact on the company's operational or strategic direction.
- Employees, Customers, Suppliers, Creditors: No direct impact is expected from this insider transaction.
Key Dates
| Date | Description |
|---|---|
| 08/13/2025 | Date Rule 10b5-1 trading plan was adopted by Michael Henderson. |
| 11/13/2025 | Date of reported common stock transactions by Michael Henderson. |
Keywords
Apogee Therapeutics, APGE, Insider Trading, Stock Sale, CEO, Form 4, 10b5-1 Plan, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.